iSpecimen

iSpecimen

ISPCPre-clinical

iSpecimen addresses a fundamental challenge in biomedical research: the inefficient and fragmented process of sourcing high-quality human biospecimens. The company's technology platform connects a global network of sample providers (hospitals, labs, biobanks) with researchers, offering access to millions of annotated specimens across numerous disease states. By digitizing and standardizing this supply chain, iSpecimen reduces procurement timelines, increases specimen accessibility, and provides a sustainable revenue model for healthcare organizations, positioning itself as a critical infrastructure player in the life sciences ecosystem.

Market Cap
$1.9M

ISPC · Stock Price

USD 0.2080.60 (-99.76%)

Historical price data

AI Company Overview

iSpecimen addresses a fundamental challenge in biomedical research: the inefficient and fragmented process of sourcing high-quality human biospecimens. The company's technology platform connects a global network of sample providers (hospitals, labs, biobanks) with researchers, offering access to millions of annotated specimens across numerous disease states. By digitizing and standardizing this supply chain, iSpecimen reduces procurement timelines, increases specimen accessibility, and provides a sustainable revenue model for healthcare organizations, positioning itself as a critical infrastructure player in the life sciences ecosystem.

Technology Platform

The iSpecimen Marketplace® is a digital platform that connects life science researchers with a global network of healthcare providers to streamline the search, procurement, and logistics of human biospecimens and associated clinical data.

Opportunities

Growth opportunities include scaling the global provider network to access billions of discarded clinical specimens, expanding into adjacent services like central lab testing or data analytics, and leveraging AI to improve specimen matching for complex research protocols.
The increasing demand for diverse, annotated biospecimens for precision medicine is a powerful tailwind.

Risk Factors

Key risks include the challenge of achieving a two-sided network effect, navigating complex and evolving global regulations for human biological materials and data, reliance on third-party providers for inventory and logistics, and competitive pressure from larger CROs and biobanks developing their own digital tools.

Competitive Landscape

Main competitors include traditional specimen brokers and large CROs (e.g., BioIVT, Discovery Life Sciences) and internal programs at large diagnostic labs. iSpecimen differentiates through its asset-light, digital marketplace model that aggregates a global network of providers, offering researchers a single point of access to a more diverse and scalable inventory than traditional brokers typically hold.

Company Info

TypeServices
LocationUnited States
StagePre-clinical
RevenueRevenue Generating

Trading

TickerISPC
ExchangeNASDAQ

Contact

ispecimen.com781-301-6700

Therapeutic Areas

COVID-19CancerAutoimmuneCardiovascularGastrointestinalCentral Nervous SystemLiver DiseaseInfectious DiseasesRespiratory DiseaseWomen's Health
SIMILAR COMPANIES
BASi Research Products
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
EydisBio
Pre-clinical · Cambridge
3Spine
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile